Sector News

Categories

Borderless Insights

Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?
Image
Mute the ‘Blah-Blah’ Leaders – it’s empathetic leaders who deserve our undivided attention

Sanofi and Evotec seal 250m-Euro strategic alliance

March 20, 2015
Life sciences
Sanofi and Evotec have now concluded negotiations over a five-year strategic alliance giving the German group 250 million Euros, including more than 40 million Euros upfront in cash.
 
The move will see Evotec acquire Sanofi’s troubled operations in Toulouse, to support collaborative research in drug discovery from screening to identification of preclinical candidates with the firm’s biotech, venture capital and academic partners. 
 
Evotec said it will provide a broad range of long-term drug discovery services to Sanofi over the next five years, centred on the core small-molecule discovery platforms in Toulouse, and will take over management of the French drugmaker’s global screening compound library.
 
And, in a “first-in class, ground-breaking ‘open innovation initiative’,” both groups will combine their libraries and offer them for screening to Evotec’s business partners, creating “one of the largest and most valuable sources of starting points for drug discovery with approx. 1,700,000 compounds available to screen”.
 
Elsewhere, Evotec and Sanofi will jointly push forward a portfolio of primarily cancer-related projects – including five advanced, preclinical projects and further discovery-stage assets – to Investigational New Drug status or other value inflection points before partnering them.
 
Werner Lanthaler, Evotec’s chief executive, said the transaction “supports our long-term strategic growth plans” and “brings significant value to [our] shareholders without the need for dilutive financing”, while Elias Zerhouni, President Global R&D for Sanofi, said it will “create a field of opportunities for our employees, while contributing to the vitality of the local ecosystem”.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

Read more
June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

Read more
June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

Read more
More news

How can we help you?

We're easy to reach